Compounds > zd 9331
Page last updated: 2024-10-15

zd 9331

Description

ZD 9331: BGC9331 was formerly known as ZD9331; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135430970
CHEMBL ID126648
SCHEMBL ID177609
SCHEMBL ID10067655
MeSH IDM0248470

Synonyms (44)

Synonym
NCI60_034390
nsc-696259
nsc696259
1h-tetrazole-5-butanoic acid,4-dihydro-2,7- dimethyl-4-oxo-6-quinazolinyl)methyl]-2-propynylamino]-2-fluorobenzoyl]amino]-, (s)-
153537-73-6
(2s)-2-((4-(((2,7-dimethyl-4-oxo-1,4-dihydroquinazolin-6-yl)methyl)(prop-2-ynyl)amino)-2-fluorobenzoyl)amino)-4-(1h-tetrazol-5-yl)butanoic acid
plevitrexed
zd 9331
nsc 696259
zd9331
1h-tetrazole-5-butanoic acid, alpha-((4-(((1,4-dihydro-2,7-dimethyl-4-oxo-6-quinazolinyl)methyl)-2-propynylamino)-2-fluorobenzoyl)amino)-, (alphas)-
plevitrexed [inn]
1h-tetrazole-5-butanoic acid, alpha-((4-(((1,4-dihydro-2,7-dimethyl-4-oxo-6-quinazolinyl)methyl)-2-propynylamino)-2-fluorobenzoyl)amino)-, (s)-
bgc9331
zd-9331
(s)-2-{4-[(2,7-dimethyl-4-oxo-3,4-dihydro-quinazolin-6-ylmethyl)-prop-2-ynyl-amino]-2-fluoro-benzoylamino}-4-(1h-tetrazol-5-yl)-butyric acid
bdbm50081252
bgc-9331
CHEMBL126648 ,
172521-94-7
(2s)-2-[[4-[(2,7-dimethyl-4-oxo-1h-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2h-tetrazol-5-yl)butanoic acid
plevitrexed [inn:ban]
bgc 9331
unii-l9p2881c3h
l9p2881c3h ,
IEJSCSAMMLUINT-NRFANRHFSA-N
(2s)-2-({4-[[(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino]-2-fluorobenzoyl}amino)-4-(1h-tetrazol-5-yl)butanoic acid
SCHEMBL177609
1h-tetrazole-5-butanoic acid, .alpha.-((4-(((1,4-dihydro-2,7-dimethyl-4-oxo-6-quinazolinyl)methyl)-2-propynylamino)-2-fluorobenzoyl)amino)-, (.alpha.s)-
plevitrexed [who-dd]
plevitrexed [mart.]
SCHEMBL10067655
gtpl8278
plevitrexed (inn)
D10803
DTXSID10165351
AKOS027461095
(2s)-2-[[4-[(2,7-dimethyl-4-oxo-3h-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2h-tetrazol-5-yl)butanoic acid
HY-13728
DB06163
Q27088412
CS-0007757
plevitrexed(nsc 696259)
(2s)-2-[[4-[(2,7-dimethyl-4-oxo-1h-quinazolin-6-yl)methyl-prop-2-ynyl-amino]-2-fluoro-benzoyl]amino]

Pharmacokinetics

ExcerptReference
" The pharmacokinetics of the classical antifolate methotrexate have been well-defined and pharmacokinetic data can be exploited to reduce the toxicity and enhance the activity of the drug."( Clinical pharmacokinetics of antitumor antifolates.
Newell, DR, 1999)
" Chromatograms and pharmacodynamic data from a Phase 1 Clinical Trial of a new antifolate drug, ZD9331 are included to illustrate the utility of the method."( Modified high-performance liquid chromatography assay for the measurement of 2'-deoxyuridine in human plasma and its application to pharmacodynamic studies of antimetabolite drugs.
Jackman, AL; Lynn, S; Mitchell, F, 2000)
" infusion on day 1 of a 4-week cycle to allow full pharmacokinetic assessment."( Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors.
Bonneterre, J; Culine, S; de Jonge, MJ; de Vries, EG; Droz, J; Glimelius, B; Smith, R; Van Groeningen, C; Verweij, J; Young, J, 2002)
" This ZD9331/docetaxel regimen does not appear to be associated with either major pharmacokinetic or toxicologic drug-drug interactions."( A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.
Garrison, M; Jones, CB; McCreery, H; Patnaik, A; Rowinsky, EK; Schwartz, GH; Skinner, M; Takimoto, C; Tolcher, AW, 2004)

Compound-Compound Interactions

ExcerptReference
" We report results from two open-label, multicentre, phase I and phase II trials, investigating the pharmacokinetics, tolerability and efficacy of ZD9331, when used in combination with topotecan in patients with relapsed or refractory tumours."( ZD9331 in combination with topotecan: phase I and II experience.
Benson, A; Poplin, E; Vergote, I, 2003)
"ZD9331, in combination with topotecan, showed manageable toxicity and some evidence of activity in patients with ovarian cancer."( ZD9331 in combination with topotecan: phase I and II experience.
Benson, A; Poplin, E; Vergote, I, 2003)
"To determine the maximum tolerated dose and dose-limiting toxicities (DLTs) of ZD9331 in combination with cisplatin in patients with refractory solid tumors and to describe any preliminary antitumor activity associated with this regimen."( Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies.
Algazy, K; Bilenker, JH; Flaherty, KT; Garcia-Vargas, JE; Giantonio, BJ; Haller, DG; Koehler, M; McLaughlin, K; O'Dwyer, PJ; Stevenson, JP, 2004)
"ZD9331 in combination with cisplatin was well tolerated at a dose of 130/50 mg/m(2) after establishing the principal DLTs of neutropenia and thrombocytopenia."( Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies.
Algazy, K; Bilenker, JH; Flaherty, KT; Garcia-Vargas, JE; Giantonio, BJ; Haller, DG; Koehler, M; McLaughlin, K; O'Dwyer, PJ; Stevenson, JP, 2004)
"To establish the recommended dose (RD) of the thymidylate-synthase inhibitor ZD9331 administered with irinotecan (CPT-11) in patients with pretreated metastatic colorectal cancer, and to assess toxicity profile, pharmacokinetics (PK), and anti-tumor activity in a phase I/II open, multicenter, intrapatient chemotherapy dose escalating trial."( A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patients.
André, T; de Gramont, A; Gamelin, E; Garcia, ML; Kalla, S; Lenaers, G; Louvet, C; Méry-Mignard, D; Saavedra, A, 2004)
"ZD9331 90 mg/m2 combined with CPT-11 180 mg/m2 may be a viable option for treatment of metastatic colorectal cancer, with possible escalation to 120 mg/m2 of ZD9331 according to safety evaluation."( A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patients.
André, T; de Gramont, A; Gamelin, E; Garcia, ML; Kalla, S; Lenaers, G; Louvet, C; Méry-Mignard, D; Saavedra, A, 2004)
" In this study, we investigated the anticancer activity of BGC9331 either alone or combined with 5-fluorouracil (5-FU), MTA (multi-target antifolate), oxali-platin and SN-38, the active metabolite of the topoisomerase I inhibitor CPT-11."( Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independen
André, T; Coudray, AM; De Gramont, A; Faivre, S; Gespach, C; Kornprobst, M; Larsen, AK; Louvet, C; Raymond, E; Tournigand, C, 2005)

Dosage Studied

ExcerptReference
" Body-surface area did not correlate with drug clearance; therefore, fixed daily dosing of 25 mg/d was studied and found to be tolerable, with two of 12 dose-limiting events."( Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations.
Averbuch, S; Bertucci, D; Douglass, E; Goh, BC; Hutchison, M; Mani, S; Ratain, MJ; Schilsky, RL; Smith, M; Smith, R; Vogelzang, NJ, 2001)
" Initially, patients were dosed at 130 mg/m2 (Regimen 1); however, following a protocol amendment, the starting dose was reduced to 65 mg/m2 (Regimen 2)."( Phase II multicentre trial of ZD9331 monotherapy as first-line treatment for gastric cancer.
Petruzelka, L, 2003)
"Nineteen patients were treated with 71 cycles of ZD9331 and docetaxel (ZD9331/docetaxel) at dose levels that encompassed dosing iterations of ZD9331 ranging from 65 to 260 mg/m(2) and docetaxel doses in the range of 50 to 75 mg/m(2)."( A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.
Garrison, M; Jones, CB; McCreery, H; Patnaik, A; Rowinsky, EK; Schwartz, GH; Skinner, M; Takimoto, C; Tolcher, AW, 2004)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thymidylate synthaseMus musculus (house mouse)IC50 (µMol)0.00140.00041.322610.0000AID212643
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID97899The compound was tested for inhibition of isolated thymidylate synthase partially purified from L1210 mouse leukemia cells1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Design and synthesis of potent non-polyglutamatable quinazoline antifolate thymidylate synthase inhibitors.
AID98199Growth inhibition of murine tumor L1210 cell line1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Design and synthesis of potent non-polyglutamatable quinazoline antifolate thymidylate synthase inhibitors.
AID212643Inhibition of isolated thymidylate synthase partially purified from L1210 mouse leukemia cells1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Design and synthesis of potent non-polyglutamatable quinazoline antifolate thymidylate synthase inhibitors.
AID99331Relative resistance ratio evaluated for murine tumor L1210:1565 cells with 10% fetal calf serum as supplement1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Design and synthesis of potent non-polyglutamatable quinazoline antifolate thymidylate synthase inhibitors.
AID99335Tested for inhibition of cell growth in culture against murine tumor L1210:RD1694 cell lines1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Design and synthesis of potent non-polyglutamatable quinazoline antifolate thymidylate synthase inhibitors.
AID99330Inhibition of cell growth in culture against murine tumor L1210:1565 cell lines1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Design and synthesis of potent non-polyglutamatable quinazoline antifolate thymidylate synthase inhibitors.
AID99336Relative resistance ratio evaluated for murine tumor L1210:RD1694 cells with 10% horse serum as supplement1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Design and synthesis of potent non-polyglutamatable quinazoline antifolate thymidylate synthase inhibitors.
AID1346054Mouse thymidylate synthetase (Nucleoside synthesis and metabolism)1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Design and synthesis of potent non-polyglutamatable quinazoline antifolate thymidylate synthase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (55)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's14 (25.45)18.2507
2000's39 (70.91)29.6817
2010's2 (3.64)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials17 (30.91%)5.53%
Reviews15 (27.27%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (41.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		4.6561nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
trimetrexate
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.		2.6930
ornithine
Ornithine: An amino acid produced in the urea cycle by the splitting off of urea from arginine.. ornithine : An alpha-amino acid that is pentanoic acid bearing two amino substituents at positions 2 and 5.		2.0110non-proteinogenic L-alpha-amino acid;
ornithine		algal metabolite;
hepatoprotective agent;
mouse metabolite
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		2.0110pyrrole;
secondary amine
thiophenes
Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.		8.64191mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
quinazolines
Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.		12.725517azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
pyrazines
Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.		2.0110diazine;
pyrazines		Daphnia magna metabolite
deoxycytidine
[no description available]		3.821pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
deoxyuridine
[no description available]		3.821pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		4.3141delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		210taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
piritrexim
piritrexim: RN given refers to parent cpd; structure given in first source		3.0910
topotecan
Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.		4.511pyranoindolizinoquinolineantineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
gemcitabine
gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.		3.411organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
irinotecan
[no description available]		4.3141carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
capecitabine
Capecitabine: A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.. capecitabine : A carbamate ester that is cytidine in which the hydrogen at position 5 is replaced by fluorine and in which the amino group attached to position 4 is converted into its N-(penyloxy)carbonyl derivative. Capecitabine is a antineoplastic agent used in the treatment of cancers.		210carbamate ester;
cytidines;
organofluorine compound		antimetabolite;
antineoplastic agent;
prodrug
deoxyuridine triphosphate
[no description available]		210deoxyuridine phosphate;
pyrimidine 2'-deoxyribonucleoside 5'-triphosphate		Arabidopsis thaliana metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite
ecteinascidin 743
[no description available]		2.0110acetate ester;
azaspiro compound;
bridged compound;
hemiaminal;
isoquinoline alkaloid;
lactone;
organic heteropolycyclic compound;
organic sulfide;
oxaspiro compound;
polyphenol;
tertiary amino compound		alkylating agent;
angiogenesis modulating agent;
anti-inflammatory agent;
antineoplastic agent;
marine metabolite
methotrexate
[no description available]		5.1180dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
talotrexin
N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine: RN refers to (S)-isomer		2.0110
docetaxel anhydrous
Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.		3.411secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
irofulven
irofulven: structure in first source		2.0110cyclohexenones
cyc 202
seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.		2.02102,6-diaminopurinesantiviral drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
formyl phosphate
[no description available]		2.0710acyl monophosphate;
one-carbon compound
aminopterin
Aminopterin: A folic acid derivative used as a rodenticide that has been shown to be teratogenic.		3.0910dicarboxylic acidEC 1.5.1.3 (dihydrofolate reductase) inhibitor;
mutagen
organophosphonates
hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.		2.0310divalent inorganic anion;
phosphite ion
bortezomib
[no description available]		2.0110amino acid amide;
L-phenylalanine derivative;
pyrazines		antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor
sesquiterpenes
[no description available]		2.0110
semaxinib
semaxanib : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is replaced by a 3,5-dimethylpyrrol-2-yl group.		2.0110olefinic compound;
oxindoles;
pyrroles		angiogenesis modulating agent;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
edatrexate
edatrexate: structure given in first source		3.0910glutamic acid derivative
ag 331
AG 331: structure given in second source		5.1140
tetracycline
Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.		210
levoleucovorin
Levoleucovorin: A folate analog consisting of the pharmacologically active isomer of LEUCOVORIN.. (6S)-5-formyltetrahydrofolic acid : The pharmacologically active (6S)-stereoisomer of 5-formyltetrahydrofolic acid.		2.4205-formyltetrahydrofolic acidantineoplastic agent;
metabolite
guanine
[no description available]		5.911002-aminopurines;
oxopurine;
purine nucleobase		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
folic acid
folcysteine: used to promote fertility in chickens. vitamin B9 : Any B-vitamin that exhibits biological activity against vitamin B9 deficiency. Vitamin B9 refers to the many forms of folic acid and its derivatives, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid amongst others. They are present in abundance in green leafy vegetables, citrus fruits, and animal products. Lack of vitamin B9 leads to anemia, a condition in which the body cannot produce sufficient number of red blood cells. Symptoms of vitamin B9 deficiency include fatigue, muscle weakness, and pale skin.		5.8190folic acids;
N-acyl-amino acid		human metabolite;
mouse metabolite;
nutrient
raltitrexed
[no description available]		8.68201N-acyl-amino acid
nolatrexed
nolatrexed: structure given in first source; RN given refers to dihydrochloride		5.6560
ici 198583
ICI 198583: RN & structure given in first source		210
1843u89
1843U89: structure given in first source; a folate analog		5.6560
pemetrexed
pemetrexed disodium : An organic sodium salt that is the disodium salt of N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT).		5.91100N-acyl-L-glutamic acid;
pyrrolopyrimidine		antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
EC 2.1.1.45 (thymidylate synthase) inhibitor;
EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
lometrexol
lometrexol: RN & structure given in first source;		4.330
cb 3717
[no description available]		210N-acyl-L-glutamic acid
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		04.2940
Blood Diseases
[description not available]		04.3622
Benign Neoplasms
[description not available]		09.681711
Hematologic Diseases
Disorders of the blood and blood forming tissues.		04.3622
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		03.3911
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		09.681711
Colorectal Cancer
[description not available]		07.283
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		07.283
Cancer of Lung
[description not available]		02.4120
Lung Neoplasms
Tumors or cancer of the LUNG.		02.4120
Thrombopenia
[description not available]		04.3622
Anemia
A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.		03.411
Neutropenia
A decrease in the number of NEUTROPHILS found in the blood.		05.4944
Thrombocytopenia
A subnormal level of BLOOD PLATELETS.		04.3622
Cancer of Pancreas
[description not available]		03.411
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		03.411
Cancer of Stomach
[description not available]		04.3622
Stomach Neoplasms
Tumors or cancer of the STOMACH.		04.3622
Colicky Pain
[description not available]		03.411
Diarrhea
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.		03.411
Abdominal Pain
Sensation of discomfort, distress, or agony in the abdominal region.		03.411
Breast Cancer
[description not available]		03.8121
Cancer of Ovary
[description not available]		06.7652
Breast Neoplasms
Tumors or cancer of the human BREAST.		03.8121
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		18.7652
Cancer of Colon
[description not available]		05.0131
Colonic Neoplasms
Tumors or cancer of the COLON.		05.0131
Cancer of Rectum
[description not available]		03.411
Rectal Neoplasms
Tumors or cancer of the RECTUM.		03.411
Leucocythaemia
[description not available]		02.6930
Acute Disease
Disease having a short and relatively severe course.		01.9910
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)		02.6930
Leukemia L5178
An experimental lymphocytic leukemia of mice.		01.9910
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		0210
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		0210
Germinoblastoma
[description not available]		0210
Lymphoma
A general term for various neoplastic diseases of the lymphoid tissue.		0210
Dermatitis Medicamentosa
[description not available]		03.3911